Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir. NV15107 Study Group.
J
J
Lalezari
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D019540:Area Under Curve; D002214:Capsules; D004305:Dose-Response Relationship, Drug; D005780:Gelatin / Q000737:chemistry; D006678:HIV / Q000187:drug effects* / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D012367:RNA, Viral / Q000032:analysis; D019258:Saquinavir / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology
D019380:Anti-HIV Agents; D002214:Capsules; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D005780:Gelatin; D019258:Saquinavir